CD7 and graft versus host disease: Targeting the universal T-cell marker CD7, this strategy involves the expression of anti-CD7 CAR through lentiviral transduction, CRISPR-Cas9 for CD7, and TCR alpha chain (TRAC) ablation to avoid fratricide and GVHD, respectively (250).